

Notice of Results

March 22, 2023

RNS Number : 7566T Renalytix PLC 22 March 2023

Renalytix plc

("Renalytix" or the "Company")

Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30

LONDON and **SALT LAKE CITY, March 22, 2023** -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial results on Thursday, March 30, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Conference Call Details:

To participate in the live conference call via telephone, please register <u>here</u>. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link:

https://edge.media-server.com/mmc/p/oub5knjk

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc

James McCullough, CEO

Www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

Investec Bank plc (Joint Broker)

Gary Clarence / Shalin Bhamra

Walbrook PR Limited

Paul McManus / Lianne Applegarth

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07584 391 303

Tel: 020 7710 7600

Tel: 020 7597 4000

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

NORJBMATMTJTBMJ